XSHE
300206
Market cap990mUSD
Oct 09, Last price
11.68CNY
1D
2.10%
1Q
-2.99%
Jan 2017
22.95%
IPO
89.54%
Name
Edan Instruments Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Edan Instruments, Inc. is a global provider specializing in the development, manufacturing, and worldwide distribution of a comprehensive range of medical equipment. Their diagnostic electrocardiograph (ECG) portfolio covers a variety of solutions, such as resting ECG, stress testing, Holter monitoring, wireless options, and dedicated ECG workstations. For patient monitoring, Edan offers systems addressing vital signs, transport, central monitoring, and various levels of care—from high acuity to acute and sub-acute settings—along with telemetry and pulse oximetry devices. In the field of obstetrics and gynecology, their offerings include fetal and maternal monitoring systems, fetal telemetry, ultrasonic Doppler devices, and video colposcopes. The company's ultrasound imaging systems encompass both color Doppler and black-and-white digital units. Additionally, Edan provides in-vitro diagnostics (IVD) like hematology analyzers, and a suite of point-of-care testing (POCT) systems, including analyzers for blood gas and chemistry, magnetic immunoassay, and colloidal gold-labeled immunoassay. They also cater to the veterinary market with specialized ultrasound, ECG, ABG, and monitoring products. Edan Instruments, Inc. maintains its headquarters in Shenzhen, People's Republic of China.
Key people
Youdong Zu
Finance Director, Vice President, Secretary of the Board, Director · since 2013
Xicheng Xie
Vice President, Director · since 2013
Shixin Yuan
Director · since 2023
Hao Zhang
Chairman of the Board, President · since 2016
Ying Wu
Independent Director
Quanlu Zheng
Independent Director · since 2022
Headquarters & legal address
深圳市坪山新区坑梓街道金沙社区金辉路15号
深圳市, GD 510000
CN
深圳市, GD 510000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||